Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy

Animesh D Pardanani, P. Brown, M. Neben-Wittich, R. Tobin, Ayalew Tefferi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The main cause of hepatosplenomegaly in primary (PMF), post polycythemia vera (post-PV MF), and post essential thrombocythemia (post-ET MF) myelofibrosis (MF) is extramedullary hematopoiesis (EMH). Drug-refractory symptomatic splenomegaly in MF is usually managed by splenectomy or involved-field radiotherapy. The latter is most effective in the treatment of MF-associated bone pain and pulmonary hypertension. Our previous experience with hepatosplenic radiotherapy in MF showed efficacy in the majority of treated patients but its utility was limited by the transient nature of its benefit and the occurrence of treatment-related pancytopenia. In an effort to address these issues, we have adopted an induction-maintenance treatment strategy that utilizes lower radiation doses-induction with 100 cGy total in four daily doses of 25 cGy and maintenance with either the same or lower intensity regimen. Herein, we report our most recent experience using this treatment plan in two cases, who in addition to their expected response from the standpoint of splenomegaly, also unexpectedly showed a marked response of their underlying accelerated phase disease, including clearance of circulating blasts and basophilia.

Original languageEnglish (US)
Pages (from-to)715-716
Number of pages2
JournalAmerican Journal of Hematology
Volume85
Issue number9
DOIs
StatePublished - 2010

Fingerprint

Primary Myelofibrosis
Radiotherapy
Splenomegaly
Extramedullary Hematopoiesis
Essential Thrombocythemia
Polycythemia Vera
Pancytopenia
Splenectomy
Therapeutics
Pulmonary Hypertension
Maintenance
Radiation
Bone and Bones
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. / Pardanani, Animesh D; Brown, P.; Neben-Wittich, M.; Tobin, R.; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 85, No. 9, 2010, p. 715-716.

Research output: Contribution to journalArticle

@article{d438545f629943b6829e0e2680ed40d3,
title = "Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy",
abstract = "The main cause of hepatosplenomegaly in primary (PMF), post polycythemia vera (post-PV MF), and post essential thrombocythemia (post-ET MF) myelofibrosis (MF) is extramedullary hematopoiesis (EMH). Drug-refractory symptomatic splenomegaly in MF is usually managed by splenectomy or involved-field radiotherapy. The latter is most effective in the treatment of MF-associated bone pain and pulmonary hypertension. Our previous experience with hepatosplenic radiotherapy in MF showed efficacy in the majority of treated patients but its utility was limited by the transient nature of its benefit and the occurrence of treatment-related pancytopenia. In an effort to address these issues, we have adopted an induction-maintenance treatment strategy that utilizes lower radiation doses-induction with 100 cGy total in four daily doses of 25 cGy and maintenance with either the same or lower intensity regimen. Herein, we report our most recent experience using this treatment plan in two cases, who in addition to their expected response from the standpoint of splenomegaly, also unexpectedly showed a marked response of their underlying accelerated phase disease, including clearance of circulating blasts and basophilia.",
author = "Pardanani, {Animesh D} and P. Brown and M. Neben-Wittich and R. Tobin and Ayalew Tefferi",
year = "2010",
doi = "10.1002/ajh.21799",
language = "English (US)",
volume = "85",
pages = "715--716",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy

AU - Pardanani, Animesh D

AU - Brown, P.

AU - Neben-Wittich, M.

AU - Tobin, R.

AU - Tefferi, Ayalew

PY - 2010

Y1 - 2010

N2 - The main cause of hepatosplenomegaly in primary (PMF), post polycythemia vera (post-PV MF), and post essential thrombocythemia (post-ET MF) myelofibrosis (MF) is extramedullary hematopoiesis (EMH). Drug-refractory symptomatic splenomegaly in MF is usually managed by splenectomy or involved-field radiotherapy. The latter is most effective in the treatment of MF-associated bone pain and pulmonary hypertension. Our previous experience with hepatosplenic radiotherapy in MF showed efficacy in the majority of treated patients but its utility was limited by the transient nature of its benefit and the occurrence of treatment-related pancytopenia. In an effort to address these issues, we have adopted an induction-maintenance treatment strategy that utilizes lower radiation doses-induction with 100 cGy total in four daily doses of 25 cGy and maintenance with either the same or lower intensity regimen. Herein, we report our most recent experience using this treatment plan in two cases, who in addition to their expected response from the standpoint of splenomegaly, also unexpectedly showed a marked response of their underlying accelerated phase disease, including clearance of circulating blasts and basophilia.

AB - The main cause of hepatosplenomegaly in primary (PMF), post polycythemia vera (post-PV MF), and post essential thrombocythemia (post-ET MF) myelofibrosis (MF) is extramedullary hematopoiesis (EMH). Drug-refractory symptomatic splenomegaly in MF is usually managed by splenectomy or involved-field radiotherapy. The latter is most effective in the treatment of MF-associated bone pain and pulmonary hypertension. Our previous experience with hepatosplenic radiotherapy in MF showed efficacy in the majority of treated patients but its utility was limited by the transient nature of its benefit and the occurrence of treatment-related pancytopenia. In an effort to address these issues, we have adopted an induction-maintenance treatment strategy that utilizes lower radiation doses-induction with 100 cGy total in four daily doses of 25 cGy and maintenance with either the same or lower intensity regimen. Herein, we report our most recent experience using this treatment plan in two cases, who in addition to their expected response from the standpoint of splenomegaly, also unexpectedly showed a marked response of their underlying accelerated phase disease, including clearance of circulating blasts and basophilia.

UR - http://www.scopus.com/inward/record.url?scp=77956463371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956463371&partnerID=8YFLogxK

U2 - 10.1002/ajh.21799

DO - 10.1002/ajh.21799

M3 - Article

C2 - 20661915

AN - SCOPUS:77956463371

VL - 85

SP - 715

EP - 716

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -